Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

Irene Catucci, Ana Osorio, Brita Arver, Guido Neidhardt, Massimo Bogliolo, Federica Zanardi, Mirko Riboni, Simone Minardi, Roser Pujol, Jacopo Azzollini, Bernard Peissel, Siranoush Manoukian, Giovanna De Vecchi, Stefano Casola, Jan Hauke, Lisa Richters, Kerstin Rhiem, Rita K. Schmutzler, Karin Wallander, Therese TörngrenÅke Borg, Paolo Radice, Jordi Surrallés, Eric Hahnen, Hans Ehrencrona, Anders Kvist, Javier Benitez, Paolo Peterlongo, Zakaria Einbeigi, Marie Stenmark-Askmalm, Annika Lindblom, Emma Tham, Beatrice Melin, Ylva Paulsson-Karlsson

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

© 2018 American College of Medical Genetics and Genomics. Purpose: Monoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer. Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS). FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations. Methods: Breast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes. Results: Five cases homozygous for FANCM loss-of-function mutations were identified. They show a heterogeneous phenotype including cancer predisposition, toxicity to chemotherapy, early menopause, and possibly chromosome fragility. Phenotype severity might correlate with mutation position in the gene. Conclusion: Our data indicate that biallelic FANCM mutations do not cause classical FA, providing proof that FANCM is not a canonical FA gene. Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene. Mutation testing of FANCM might be considered for individuals with the above-described clinical features.
Original languageEnglish
Pages (from-to)452-457
JournalGenetics in Medicine
Volume20
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • FA-like disease
  • Fanconi anemia
  • biallelic FANCM mutations
  • breast cancer risk factors
  • genotype/phenotype correlation

Fingerprint Dive into the research topics of 'Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility'. Together they form a unique fingerprint.

Cite this